Femasys IncFEMY
▲ PositiveRegulationTechnologyrelevance
Regained Nasdaq compliance, securing continued listing.
Impact on stocks 1
Health Care
Femasys IncFemasys Regains Nasdaq Compliance, Continues Reproductive Health Pipeline Push
Regulation
Femasys has regained compliance with Nasdaq's minimum bid price requirement, securing its continued listing. CEO Kathy Lee-Sepsick called the milestone important for the company and its shareholders, emphasizing the focus on advancing strategic priorities and expanding access to reproductive health solutions. The company is commercializing a portfolio of fertility and permanent birth control products, including FemaSeed Intratubal Insemination, which has shown more than double the pregnancy rate of traditional intrauterine insemination in published clinical data, as well as FemVue, FemHSG Catheter, and FemBloc, the first non-surgical, in-office permanent birth control alternative that has received regulatory approvals in Europe, the UK, and New Zealand. Enrollment is ongoing in the pivotal FINALE trial for FemBloc to seek U.S. FDA approval. The stock closed Wednesday at $3.67, down 8.48%, and was at $3.65 in after-hours trading.
Femasys IncRegained Nasdaq compliance, securing continued listing.